Immunotherapy, Gene Editing Advances Extend to Type 1 Diabetes (VIDEO)

Seattle Children's

Caption

Advances in engineering T cells to treat cancer are paving the way for new immunotherapies targeted at autoimmune diseases, including type 1 diabetes. Now, researchers at Seattle Children's Research Institute and Benaroya Research Institute at Virginia Mason are working together to investigate therapies that reprogram T cells to "turn down" an immune response, which may hold promise for curing type 1 diabetes, as well as a number of diseases where overactive T cells attack a person's healthy cells and organs.

Credit

Seattle Children's

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.